The lawsuit filed on [the Plaintiff's] behalf alleges that the Defendants knew about the risk of bladder cancer but did not disclose this information...
New York, New York (PRWEB) June 25, 2013
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of an Oklahoma man who developed bladder cancer and subsequently died, allegedly after taking the diabetes drug Actos (pioglitazone). The suit was filed on May 23, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1237). It is one of thousands of cases that have been filed as part of the multidistrict litigation (MDL) entitled In Re: Actos (pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants. Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation.
According to the Complaint, the Plaintiff started taking Actos to treat his Type 2 diabetes in November 2008. In January 2010, he was diagnosed with bladder cancer. He died in October 2012, allegedly because of Actos’ side effects. The lawsuit filed on his behalf alleges that the Defendants knew about the risk of bladder cancer but did not disclose this information to consumers in order to protect financial interests. The Plaintiff alleges that Actos caused pain and suffering, emotional distress and substantially reduced the Plaintiff’s ability to enjoy life. The suit is also seeking damages for loss of consortium on behalf of the Plaintiff’s spouse.
On June 15, 2011, the U.S. Food and Drug Administration (FDA) warned that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk.
Some research studies support the notion of a link between Actos and bladder cancer. The British Medical Journal published a study on May 31, 2012, that revealed Actos users were twice as likely to develop bladder cancer after two years. Then, on July 3, 2012, the Canadian Medical Association Journal reported that patients taking the medication were 22 percent more likely to get bladder cancer.
Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney